July 16, 2026

Growth hormone secretagogues (GHSs) are a broad class of compounds studied for their ability to stimulate the endogenous release of growth hormone from the anterior pituitary. They are a recurring subject in endocrinology, metabolic, and musculoskeletal research models. This overview covers the main mechanistic classes, the analytical standards that separate reliable material from questionable material, and the practical points Canadian labs should weigh when sourcing.
All compounds discussed here are sold for research use only and are not for human consumption. Nothing below describes dosing, administration, or protocols.
A growth hormone secretagogue is any molecule that promotes growth hormone (GH) secretion through a receptor-mediated pathway rather than by supplying GH directly. That distinction matters for study design. GHSs act upstream of the hormone itself, which makes them useful tools for investigating the regulatory machinery of the GH axis.
Two receptor systems dominate the literature:
Because these two pathways are distinct, compounds acting on them are often studied together in models designed to probe synergistic or additive signaling.
GHRH analogs are peptides modeled on growth hormone-releasing hormone. They bind GHRH-R and are frequently used in research examining pituitary responsiveness. Sermorelin, a truncated GHRH fragment, and tesamorelin, a stabilized analog, are common reference compounds in this class. CJC-1295 is another peptide studied for its extended half-life properties in this category.
Structurally, these are peptide sequences, which means they carry the usual stability considerations: susceptibility to enzymatic cleavage, sensitivity to repeated freeze-thaw, and the need for cold-chain handling.
Growth hormone-releasing peptides (GHRPs) and other ghrelin mimetics act on GHS-R1a. This group includes GHRP-2, GHRP-6, hexarelin, and ipamorelin. They are studied for their effect on the ghrelin signaling axis and, in some models, for downstream metabolic and appetite-related pathways.
Ipamorelin is often highlighted in research literature for its comparatively selective profile relative to earlier GHRPs, which is one reason it appears frequently in study designs comparing secretagogue selectivity.
Some GHS-R1a agonists are small molecules rather than peptides. MK-677 (ibutamoren) is the best known. As an orally bioavailable, non-peptide compound, it behaves differently in storage and handling than the peptides above. Small molecules generally tolerate ambient conditions better than peptides, but batch purity and identity verification remain just as important.
The single most useful thing you can do when sourcing GHSs is read the analytical data. A compound is only as good as its documentation.
A supplier that provides a batch-specific Certificate of Analysis (CoA) with these methods is giving you something you can build an experiment on. A generic, undated CoA reused across lots is not.
Lyophilized peptides are generally stable for extended periods when stored cold and dry. Most research peptides in this class are shipped as a lyophilized powder and are commonly stored at -20°C for long-term stability, with many stable at 2–8°C for shorter working periods. Protection from light and moisture is standard practice.
Once reconstituted, peptides are far less stable and are typically kept refrigerated and used within a short window. Repeated freeze-thaw cycles degrade peptide integrity, so aliquoting reconstituted material is a common lab practice to avoid it.
Non-peptide secretagogues like MK-677 have different stability characteristics and should be stored according to their specific CoA guidance.
Researchers often use a Peptide Calculator to standardize concentrations across experiments, which helps keep reconstitution consistent between lots and between team members.
These are the errors that most often compromise a study before it starts:
GHS compounds sold for laboratory work in Canada are supplied strictly as research chemicals. Labeling should clearly state research use only, not for human consumption. This framing is not boilerplate — it reflects the legal and ethical boundary of how these materials may be used.
When sourcing, choose a supplier that labels lots clearly, provides batch documentation, and answers direct questions about testing. Peptide Depot is a Canadian supplier that maintains this documentation standard for its research catalog. You can review general sourcing and handling questions on the FAQ page.
GHRH analogs act on the growth hormone-releasing hormone receptor (GHRH-R), while GHRPs and other ghrelin mimetics act on the growth hormone secretagogue receptor (GHS-R1a). They stimulate the growth hormone axis through two distinct receptor pathways, which is why they are often studied together in research models.
They can be supplied in Canada strictly as research chemicals labeled for research use only and not for human consumption. They are not sold as medicines or supplements. Researchers should confirm that any material they purchase is clearly labeled for laboratory research and comes with proper documentation.
At minimum, look for HPLC to confirm purity percentage and mass spectrometry to confirm molecular identity. Karl Fischer titration for water content and endotoxin testing for biological assay work add further confidence. All of this should appear on a batch-specific Certificate of Analysis.
Lyophilized peptides in this class are commonly stored at -20°C for long-term stability and kept dry and protected from light. Many are stable at 2–8°C for shorter working periods. Reconstituted material is less stable, should be refrigerated, and repeated freeze-thaw cycles should be avoided by aliquoting.
No. MK-677 (ibutamoren) is a non-peptide small molecule that acts as a GHS-R1a agonist. Because it is not a peptide, it has different storage and handling characteristics than peptide secretagogues, though batch purity and identity verification remain equally important.